作者:
O'Neill, PM [1]
;
Shone, AE [2]
;
Stanford, D [3]
;
Nixon, G [4]
;
Asadollahy, E [5]
;
Park, BK [6]
;
Maggs, JL ;
Roberts, P ;
Stocks, PA ;
Biagini, G ;
Bray, PG ;
Davies, J ;
Berry, N ;
Hall, C ;
Rimmer, K ;
Winstanley, PA ;
Hindley, S ;
Bambal, RB ;
Davis, CB ;
Bates, M ;
Gresham, SL
作者单位:
GlaxoSmithKline Inc, Med Res Ctr, Stevenage SG1 2NY, Herts, England.
[1]
Univ Liverpool, Liverpool Sch Trop Med, Liverpool L3 5QA, Merseyside, England.
[2]
GlaxoSmithKline Inc, Safety Assessment, Welwyn Garden City AL6 9AR, Herts, England.
[3]
Univ Liverpool, Dept Chem, Liverpool L69 7ZD, Merseyside, England.
[4]
Univ Liverpool, Sch Biomed Sci, Dept Pharmacol & Therapeut, MRC Ctr Drug Safety Sci, Liverpool L69 3GE, Merseyside, England.
[5]
GlaxoSmithKline Drug Discovery, Drug Metab & Pharmacokinet, Collegeville, PA 19426 USA.
[6]
发布时间
2013-11-20